Therapeutic Outcomes of Isatin and Its Derivatives against Multiple Diseases: Recent Developments in Drug Discovery

Rameshwar S. Cheke and Vaishali M. Patil and Sandip D. Firke and Jaya P. Ambhore and Iqrar A. Ansari and Harun M. Patel and Sachin D. Shinde and Visweswara Rao Pasupuleti and Md Imtaiyaz Hassan and Mohd Adnan and Adel Kadri and Mejdi Snoussi (2022) Therapeutic Outcomes of Isatin and Its Derivatives against Multiple Diseases: Recent Developments in Drug Discovery. Pharmaceuticals, 15. pp. 1-34. ISSN 1424-8247

[img] Text
Therapeutic Outcomes of Isatin and Its Derivatives against Multiple Diseases.pdf

Download (40kB)
[img] Text
Therapeutic Outcomes of Isatin and Its Derivatives against Multiple Diseases1.pdf
Restricted to Registered users only

Download (3MB) | Request a copy

Abstract

Isatin (1H indole 2, 3-dione) is a heterocyclic, endogenous lead molecule recognized in humans and different plants. The isatin nucleus and its derivatives are owed the attention of researchers due to their diverse pharmacological activities such as anticancer, anti-TB, antifungal, antimicrobial, antioxidant, anti-inflammatory, anticonvulsant, anti-HIV, and so on. Many research chemists take advantage of the gentle structure of isatins, such as NH at position 1 and carbonyl functions at positions 2 and 3, for designing biologically active analogues via different approaches. Literature surveys based on reported preclinical, clinical, and patented details confirm the multitarget profile of isatin analogues and thus their importance in the field of medicinal chemistry as a potent chemotherapeutic agent. This review represents the recent development of isatin analogues possessing potential pharmacological action in the years 2016–2020. The structure–activity relationship is also discussed to provide a pharmacophoric pattern that may contribute in the future to the design and synthesis of potent and less toxic therapeutics.

Item Type: Article
Uncontrolled Keywords: Chemotherapeutic agent , Anticancer drugs , Isatin derivatives , Drug design and development , Heterocyclic compounds , Therapeutic targeting
Subjects: R Medicine > RC Internal medicine > RC31-1245 Internal medicine > RC254-282 Neoplasms. Tumors. Oncology Including cancer and carcinogens
R Medicine > RM Therapeutics. Pharmacology > RM1-950 Therapeutics. Pharmacology > RM300-666 Drugs and their actions
Divisions: FACULTY > Faculty of Medicine and Health Sciences
Depositing User: SITI AZIZAH BINTI IDRIS -
Date Deposited: 15 Aug 2022 11:41
Last Modified: 15 Aug 2022 11:41
URI: https://eprints.ums.edu.my/id/eprint/33760

Actions (login required)

View Item View Item